NCT05813015

Study of Comparing of With and Without Sequential Therapy of S-1

Comparison of With and Without Sequential Single Drug Therapy of S-1 After Adjuvant Chemotherapy With Docetaxel Plus S-1 in Stage III Gastric Cancer

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 70 (estimated)
• Sponsor: Zhejiang University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The goal of this single arm clinical trial is to learn about sequential S-1 adjuvant therapy in patient wich locally advanced gastric cancer. The main question it aims to answer is: • The efficacy and safety of S-1 adjuvant therapy, following D2 radical surgery and DS(Docetaxel + S-1) adjuvant chemotherapy. All patients with locally advanced gastric cancer will received D2 radical surgery, 6 cycles of DS chemotherapy, and sequential S-1 chemotherapy up to 1 year postoperation.

Conditions

• Locally Advanced Gastric Adenocarcinoma
• Chemotherapy Effect

Interventions

Type	Name	Description
DRUG	Docetaxel	Docetaxel 40mg/m2，every 21 days，6 cycles.
DRUG	Tegafur-Gimeracil-Oteracil	S-1 40-60mg/m2，p.o, BID, day 1-14, till 1 year postoperation.

Timeline

• Start date: 2023-01-28
• Primary completion: 2026-12-31
• Completion: 2026-12-31
• First posted: 2023-04-14
• Last updated: 2023-04-14

Locations

1 site across 1 country: China